US Anti-CD19 CAR-T Cell Therapy Data
페이지 정보
Author HK HIS Date19-09-16 18:19 View290 Comment0관련링크
본문
US Anti-CD19 CAR-T Cell Therapy Data
SS,et al.N Engl J Med, published on December 10,2017
Beijing Cancer Hospital Medical Treatment Data
Clinical trials of the CD19 CAR-T study, which focuses on both China and the United States, were conducted on patients with T-cell hematopoietic and malignant lymphocytic tumors. The two countries have shown very high levels of response rates in their respective trials, reaching 66.9% (China) and 68.5% (US), respectively.
